Monthly Prescribing Reference26d
Belzutifan Gets Priority Review for Advanced Pheochromocytoma and Paraganglioma
Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no ...
Nature3y
The first FDA approved treatment for ultra-rare endocrine tumors
Patients diagnosed with pheochromocytoma or paraganglioma, tumors that form within certain endocrine tissues, such as the adrenal glands, may have abnormal endocrine activity due to the synthesis ...
Santa Rosa Press Democrat7d
North Bay triathlete with terminal cancer diagnosis writes inspiring letter to himself on ‘CBS Mornings’
Jonathan Pascual, who completed the Ironman World Championships last month, reflected on his battle with cancer during a segment on “‘CBS Mornings.” ...
Pharm Exec26d
FDA Grants Priority Review to Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
Pharmabiz24d
US FDA grants priority review status to Merck’s sNDA for Welireg to treat patients with advanced pheochromocytoma and paraganglioma
The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumours that form in and around the adrenal glands, and ...
Morningstar26d
Merck Gets FDA Priority Review of Welireg in Rare Adrenal Tumors
The Rahway, N.J., drugmaker on Monday said the application covers Welireg for patients 12 years and older with advanced, unresectable or metastatic pheochromocytoma and paraganglioma. The FDA ...